|Dr. Sean Michael Hall||MD, CEO & Director||492.77k||N/A||N/A|
|Mr. Kerem Kaya||CFO, COO & Company Sec.||82.69k||N/A||N/A|
|Mr. Ian Curtinsmith||Chief Information Officer||208.39k||N/A||N/A|
|Dr. Luis Vitetta BSc(Hons), Grad Dip, Grad Dip Nutr, Ph.D.||Director of Medical Research||278.28k||N/A||N/A|
|Dr. David A. Rutolo (USA), J.D., Ph.D.||Director of Science||183.97k||N/A||N/A|
|Mr. Tony Potter||Head of Pharmaceuticals||N/A||N/A||N/A|
Medlab Clinical Limited, a biotechnology company, researches, develops, and commercializes pharmaceutical and nutraceutical products in Australia. Its lead drug candidate includes NanaBis, an orobuccal administered equimolar tetrahydrocannabinol (THC) and cannabidiol (CBD) formulation as monotherapy, which is in phase 3 multi-centre, quadruple-blind, randomized- withdrawal active, and placebo-controlled clinical study for the management of opioid-requiringbonepain due to metastatic cancer. The company also develops NanoCelle, a patented sub-micron drug delivery platform that enhances drug solubility issues and enables faster absorption and metabolism of active ingredients. In addition, it offers vitamins and supplements; and virtual clinic services. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.
Medlab Clinical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.